Financings in Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Plans secondary offering of 5 mil. shares through Raymond James and Associates, NatWest Securities Limited, and Salomon Brothers. The Minneapolis-based manufacturer of defibrillators and radio frequency catheter ablation devices says proceeds will support "expansion of clinical trials, research and development, scale-up and expansion of the company's manufacturing and marketing, potential acquisitions of businesses, products and technologies, and general corporate purposes, including working capital"...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.